Viet Le, MPAS PA-C FACC FAHANov 29, 2022

Reviewing #AHA22 on demand. @kewatson, thank you for your wonderful discussion on the PROMINENT trial

1) fibrates in the statin era, do not lower CV risk
2) fibrates do lower trigs, consider for pancreatitis risk
3) room for NAFLD/NASH? 🤔
#CardioTwitter #LLT

Rohan Khera Nov 29, 2022

A terrific #AHA22 update by star #YaleCardiology fellows.

#STRONGHF #BESTCLI #ISCHEMIA_EXTEND #EMPAKidney #DCP #CRISPR

Watch full video here:
youtu.be/9NqCGPe7POM

CarDS LabNov 17, 2022

Nice profile on lab member Veer Sangha on his recent accomplishments at #aha22.

With quotes from members @rohankhera and Evangelos Oikonomou #YaleCardiology #YaleMed

#ML #MachineLearning #DeepLearning #DataScience #CarDSLab

https://yaledailynews.com/blog/2022/11/15/profile-veer-sangha-wins-elizabeth-barrett-connor-research/

PROFILE: Veer Sangha Wins Elizabeth Barrett-Connor Research

The Ezra Stiles College senior won the prestigious award for his development of equitable heart disease diagnosis technology.

Yale Daily News
Edgar V. Lerma 🇵🇭Nov 13, 2022

EMPA-KIDNEY: Among a wide range of patients w/ CKD who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from CV causes (vs. placebo) ca. 2022
#KidneyWk #AHA22 #Nephpearls

👉🏼 https://www.nejm.org/doi/full/10.1056/NEJMoa2204233

Empagliflozin in Patients with Chronic Kidney Disease | NEJM

Original Article from The New England Journal of Medicine — Empagliflozin in Patients with Chronic Kidney Disease

New England Journal of Medicine
Jordy Cohen, MD, MSCENov 11, 2022
@mike_johansen @hswapnil I wonder if, with all of the #LBCT publications in the past week from #KidneyWk and #AHA22, we can take overflow here. I'm usually not available during the twitter timeslot but would love to participate in one on one of the new resistant #hypertension meds 😎 🤓
Philipp Grätzel von GrätzNov 7, 2022

Das ist ein ganz schöner Knaller #AHA22 Tagung in Chicago: #ProgressiveAF Studie, eine Verlängerung der vor 2J vorgestellten #EarlyAF Studie zum Vergleich Kryoballon-Ablation vs. medikamentöse Rhythmuskontrolle in der Initial- (!)Therapie bei (1/3)

https://www.nejm.org/doi/full/10.1056/NEJMoa2212540?query=featured_home

Progression of Atrial Fibrillation after Cryoablation or Drug Therapy | NEJM

Original Article from The New England Journal of Medicine — Progression of Atrial Fibrillation after Cryoablation or Drug Therapy

New England Journal of Medicine
Philipp Grätzel von GrätzNov 7, 2022
Was hältst Du von den ECMO-CS Ergebnissen, @[email protected] ? Überraschend? Wie früh oder nicht früh wird die ECMO in Deutschland üblicherweise eingesetzt bei CS? Oder kommt hier eh eher erstmal ne andere Kreislaufunterstützung? #AHA22
https://www.healio.com/news/cardiology/20221106/early-ecmo-does-not-improve-outcomes-vs-conservative-strategy-in-cardiogenic-shock
Tejas Patel MD Nov 7, 2022
No win for supplements…fish oil, cinnamon, garlic, turmeric, plant sterols or red yeast rice!!!
#AHA22 #AHA2022 https://www.jacc.org/doi/10.1016/j.jacc.2022.10.013
Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers:

Journal of the American College of Cardiology
Scott Auerbach MD Nov 6, 2022
Congrats @jen_conway1 @seema_mital @NakanoStephanie @marcrichmond1 @JediJeewa
---
RT @CircAHA
#JustPublished: #AHA22 #CIRCAHA22 :The Prevalence and Association of Exercise Test Abnormalities with Sudden Cardiac Death and Transplant-free Survival in Childhood Hypertrophic Cardiomyopathy #AHAJournals https://ahajrnls.org/3Dxo5qM
https://twitter.com/CircAHA/status/1589260105400389632
The Prevalence and Association of Exercise Test Abnormalities with Sudden Cardiac Death and Transplant-Free Survival in Childhood Hypertrophic Cardiomyopathy

Background: Hypertrophic cardiomyopathy (HCM) can be associated with an abnormal exercise response. In adults with HCM, an abnormal exercise stress test is predictive of heart failure outcomes. Our g

Circulation